The global antitumor drug market is expected to grow at a CAGR of 4.5% during the forecast period, from 2021 to 2030. The growth of this market is driven by the increasing incidence of cancer and rise in awareness about cancer treatment. The major factors driving the growth of this market are increasing incidence of cancer, rise in awareness about cancer treatment, and technological advancements in drug development. However, high cost associated with these drugs may hamper the growth of this market during the forecast period.
Cytotoxic drugs accounted for a major share in 2017 owing to their ability to kill rapidly dividing cells such as tumor cells and normal cells that divide rapidly such as blood cells or hair follicles. These drugs are used for treating various types of cancers including leukemia, lymphoma, Hodgkin's disease, multiple myeloma and other cancers that affect organs such as breast or prostate gland. Nocytotoxic drugs accounted for a major share in 2017 owing to their ability to inhibit cell division by blocking DNA synthesis or by inhibiting mitosis which leads to death due to lack of energy production within the cell nucleus which eventually leads into apoptosis (programmed cell death). These drugs are used for treating various types of cancers including leukemia and lymphoma among others. Anttumor dru accounted for a major share in 2017 owing mainly due its use against tumors caused by viruses like human papillomavirus (HPV) which causes cervical cancer among others; it also has an effect on tumors caused by bacteria like Helicobacter pylori which causes stomach ulcers among others; it also has an effect on tumors caused by fungi like Candida albicans which causes thrush among others; it also has an effect on tumors caused by parasites like Plasmodium falciparum which causes malaria among others; it also has an effect on tumors caused by protozoa like Toxoplasma gondii which causes toxoplasmosis among others; it also has an effect on tumors caused by helminths like Schistosoma haematobium which cause bladder schistosomiasis among others; it also has an effect on tumors induced due exposure from radiation therapy or chemotherapy agents such as cisplatin-based chemotherapy agents or doxorubicin-based chemotherapy agents respectively etc; these drugs are used for treating various types of cancers including lung carcinomas etc; these drugs are used for treating various types of cancers including lung carcinomas etc; these drugs are used for treating various types of cancers including lung carcinomas etc; these drugs are used for treating various types with different mechanisms involved such as breast carcinomas etc, prostate carcinomas etc, colon adenocarcinomas etc, pancreatic adenocarcinomas et al.
Some Of The Growth Factors Of This Market:
- The increasing number of cancer cases in developing countries such as China and India is also expected to fuel the growth of this market over the forecast period (2017-2022).
Industry Growth Insights published a new data on “Anti-tumor Drug Market”. The research report is titled “Anti-tumor Drug Market research by Types (Cytotoxic Drugs, Non-cytotoxic Drugs, Anti-tumor Dru), By Applications (Alkylating Agents, Anti-metabolism Drugs, Platinum Antineoplastic Agents, Anthracycline antitumor drugs, Microtubule Stabilizer, Endocrine Therapy Drugs, Immunotherapy Drugs, Gene Therapy Drugs, Targeted Antineoplastic Drugs), By Players/Companies Roche, Novartis, Celgene, Bristol-Myers Squibb, Amgen, Johnson & Johnson, Pfizer, Takeda, Eli Lilly, AstraZeneca, Astellas, Merck & Co, Sanofi, Bayer, Biogen Idec, Eisai, Teva, Otsuka, Anti-tumor Dru”.
Scope Of The Report
Report Attributes
Report Details
Report Title
Anti-tumor Drug Market Research Report
By Type
Cytotoxic Drugs, Non-cytotoxic Drugs, Anti-tumor Dru
By Application
Alkylating Agents, Anti-metabolism Drugs, Platinum Antineoplastic Agents, Anthracycline antitumor drugs, Microtubule Stabilizer, Endocrine Therapy Drugs, Immunotherapy Drugs, Gene Therapy Drugs, Targeted Antineoplastic Drugs
By Companies
Roche, Novartis, Celgene, Bristol-Myers Squibb, Amgen, Johnson & Johnson, Pfizer, Takeda, Eli Lilly, AstraZeneca, Astellas, Merck & Co, Sanofi, Bayer, Biogen Idec, Eisai, Teva, Otsuka, Anti-tumor Dru
Regions Covered
North America, Europe, APAC, Latin America, MEA
Base Year
2021
Historical Year
2019 to 2020 (Data from 2010 can be provided as per availability)
Forecast Year
2030
Number of Pages
249
Number of Tables & Figures
175
Customization Available
Yes, the report can be customized as per your need.
Global Anti-tumor Drug Market Report Segments:
The global Anti-tumor Drug market is segmented on the basis of:
Types
Cytotoxic Drugs, Non-cytotoxic Drugs, Anti-tumor Dru
The product segment provides information about the market share of each product and the respective CAGR during the forecast period. It lays out information about the product pricing parameters, trends, and profits that provides in-depth insights of the market. Furthermore, it discusses latest product developments & innovation in the market.
Applications
Alkylating Agents, Anti-metabolism Drugs, Platinum Antineoplastic Agents, Anthracycline antitumor drugs, Microtubule Stabilizer, Endocrine Therapy Drugs, Immunotherapy Drugs, Gene Therapy Drugs, Targeted Antineoplastic Drugs
The application segment fragments various applications of the product and provides information on the market share and growth rate of each application segment. It discusses the potential future applications of the products and driving and restraining factors of each application segment.
Some of the companies that are profiled in this report are:
- Roche
- Novartis
- Celgene
- Bristol-Myers Squibb
- Amgen
- Johnson & Johnson
- Pfizer
- Takeda
- Eli Lilly
- AstraZeneca
- Astellas
- Merck & Co
- Sanofi
- Bayer
- Biogen Idec
- Eisai
- Teva
- Otsuka
- Anti-tumor Dru
Highlights of The Anti-tumor Drug Market Report:
- The market structure and projections for the coming years.
- Drivers, restraints, opportunities, and current trends of market.
- Historical data and forecast.
- Estimations for the forecast period 2030.
- Developments and trends in the market.
- By Type:
- Cytotoxic Drugs
- Non-cytotoxic Drugs
- Anti-tumor Dru
- By Application:
- Alkylating Agents
- Anti-metabolism Drugs
- Platinum Antineoplastic Agents
- Anthracycline antitumor drugs
- Microtubule Stabilizer
- Endocrine Therapy Drugs
- Immunotherapy Drugs
- Gene Therapy Drugs
- Targeted Antineoplastic Drugs
- Market scenario by region, sub-region, and country.
- Market share of the market players, company profiles, product specifications, SWOT analysis, and competitive landscape.
- Analysis regarding upstream raw materials, downstream demand, and current market dynamics.
- Government Policies, Macro & Micro economic factors are also included in the report.
We have studied the Anti-tumor Drug Market in 360 degrees via. both primary & secondary research methodologies. This helped us in building an understanding of the current market dynamics, supply-demand gap, pricing trends, product preferences, consumer patterns & so on. The findings were further validated through primary research with industry experts & opinion leaders across countries. The data is further compiled & validated through various market estimation & data validation methodologies. Further, we also have our in-house data forecasting model to predict market growth up to 2030.
Regional Analysis
- North America
- Europe
- Asia Pacific
- Middle East & Africa
- Latin America
Note: A country of choice can be added in the report at no extra cost. If more than one country needs to be added, the research quote will vary accordingly.
The geographical analysis part of the report provides information about the product sales in terms of volume and revenue in regions. It lays out potential opportunities for the new entrants, emerging players, and major players in the region. The regional analysis is done after considering the socio-economic factors and government regulations of the countries in the regions.
How you may use our products:
- Correctly Positioning New Products
- Market Entry Strategies
- Business Expansion Strategies
- Consumer Insights
- Understanding Competition Scenario
- Product & Brand Management
- Channel & Customer Management
- Identifying Appropriate Advertising Appeals
8 Reasons to Buy This Report
- Includes a Chapter on the Impact of COVID-19 Pandemic On the Market
- Report Prepared After Conducting Interviews with Industry Experts & Top Designates of the Companies in the Market
- Implemented Robust Methodology to Prepare the Report
- Includes Graphs, Statistics, Flowcharts, and Infographics to Save Time
- Industry Growth Insights Provides 24/5 Assistance Regarding the Doubts in the Report
- Provides Information About the Top-winning Strategies Implemented by Industry Players.
- In-depth Insights On the Market Drivers, Restraints, Opportunities, and Threats
- Customization of the Report Available
Frequently Asked Questions?
An anti-tumor drug is a medication that is used to treat cancer.
Some of the major players in the anti-tumor drug market are Roche, Novartis, Celgene, Bristol-Myers Squibb, Amgen, Johnson & Johnson, Pfizer, Takeda, Eli Lilly, AstraZeneca, Astellas, Merck & Co, Sanofi, Bayer, Biogen Idec, Eisai, Teva, Otsuka, Anti-tumor Dru.
The anti-tumor drug market is expected to register a CAGR of 4.5%.
1. Executive Summary
2. Assumptions and Acronyms Used
3. Research Methodology
4. Anti-tumor Drug Market Overview
4.1. Introduction
4.1.1. Market Taxonomy
4.1.2. Market Definition
4.2. Macro-Economic Factors
4.2.1. Industry Outlook
4.3. Anti-tumor Drug Market Dynamics
4.3.1. Market Drivers
4.3.2. Market Restraints
4.3.3. Opportunity
4.3.4. Market Trends
4.4. Anti-tumor Drug Market - Supply Chain
4.5. Global Anti-tumor Drug Market Forecast
4.5.1. Anti-tumor Drug Market Size (US$ Mn) and Y-o-Y Growth
4.5.2. Anti-tumor Drug Market Size (000 Units) and Y-o-Y Growth
4.5.3. Anti-tumor Drug Market Absolute $ Opportunity
5. Global Anti-tumor Drug Market Analysis and Forecast by Type
5.1. Market Trends
5.2. Introduction
5.2.1. Basis Point Share (BPS) Analysis by Type
5.2.2. Y-o-Y Growth Projections by Type
5.3. Anti-tumor Drug Market Size and Volume Forecast by Type
5.3.1. Cytotoxic Drugs
5.3.2. Non-cytotoxic Drugs
5.3.3. Anti-tumor Dru
5.4. Absolute $ Opportunity Assessment by Type
5.5. Market Attractiveness/Growth Potential Analysis by Type
6. Global Anti-tumor Drug Market Analysis and Forecast by Application
6.1. Market Trends
6.2. Introduction
6.2.1. Basis Point Share (BPS) Analysis by Application
6.2.2. Y-o-Y Growth Projections by Application
6.3. Anti-tumor Drug Market Size and Volume Forecast by Application
6.3.1. Alkylating Agents
6.3.2. Anti-metabolism Drugs
6.3.3. Platinum Antineoplastic Agents
6.3.4. Anthracycline antitumor drugs
6.3.5. Microtubule Stabilizer
6.3.6. Endocrine Therapy Drugs
6.3.7. Immunotherapy Drugs
6.3.8. Gene Therapy Drugs
6.3.9. Targeted Antineoplastic Drugs
6.4. Absolute $ Opportunity Assessment by Application
6.5. Market Attractiveness/Growth Potential Analysis by Application
7. Global Anti-tumor Drug Market Analysis and Forecast by Sales Channel
7.1. Market Trends
7.2. Introduction
7.2.1. Basis Point Share (BPS) Analysis by Sales Channel
7.2.2. Y-o-Y Growth Projections by Sales Channel
7.3. Anti-tumor Drug Market Size and Volume Forecast by Sales Channel
7.3.1. Manufacturer/Distributor/Service Provider
7.3.2. Aftermarket
7.4. Absolute $ Opportunity Assessment by Sales Channel
7.5. Market Attractiveness/Growth Potential Analysis by Sales Channel
8. Global Anti-tumor Drug Market Analysis and Forecast by Region
8.1. Market Trends
8.2. Introduction
8.2.1. Basis Point Share (BPS) Analysis by Region
8.2.2. Y-o-Y Growth Projections by Region
8.3. Anti-tumor Drug Market Size and Volume Forecast by Region
8.3.1. North America
8.3.2. Latin America
8.3.3. Europe
8.3.4. Asia Pacific
8.3.5. Middle East and Africa (MEA)
8.4. Absolute $ Opportunity Assessment by Region
8.5. Market Attractiveness/Growth Potential Analysis by Region
8.6. Global Anti-tumor Drug Demand Share Forecast, 2019-2026
9. North America Anti-tumor Drug Market Analysis and Forecast
9.1. Introduction
9.1.1. Basis Point Share (BPS) Analysis by Country
9.1.2. Y-o-Y Growth Projections by Country
9.2. North America Anti-tumor Drug Market Size and Volume Forecast by Country
9.2.1. U.S.
9.2.2. Canada
9.3. Absolute $ Opportunity Assessment by Country
9.4. North America Anti-tumor Drug Market Size and Volume Forecast by Application
9.4.1. Alkylating Agents
9.4.2. Anti-metabolism Drugs
9.4.3. Platinum Antineoplastic Agents
9.4.4. Anthracycline antitumor drugs
9.4.5. Microtubule Stabilizer
9.4.6. Endocrine Therapy Drugs
9.4.7. Immunotherapy Drugs
9.4.8. Gene Therapy Drugs
9.4.9. Targeted Antineoplastic Drugs
9.5. Basis Point Share (BPS) Analysis by Application
9.6. Y-o-Y Growth Projections by Application
9.7. North America Anti-tumor Drug Market Size and Volume Forecast by Type
9.7.1. Cytotoxic Drugs
9.7.2. Non-cytotoxic Drugs
9.7.3. Anti-tumor Dru
9.8. Basis Point Share (BPS) Analysis by Type
9.9. Y-o-Y Growth Projections by Type
9.10. Market Attractiveness/Growth Potential Analysis
9.10.1. By Country
9.10.2. By Product Type
9.10.3. By Application
9.10.4. By Sales Channel
9.11. North America Anti-tumor Drug Demand Share Forecast, 2019-2026
10. Latin America Anti-tumor Drug Market Analysis and Forecast
10.1. Introduction
10.1.1. Basis Point Share (BPS) Analysis by Country
10.1.2. Y-o-Y Growth Projections by Country
10.1.3. Latin America Average Pricing Analysis
10.2. Latin America Anti-tumor Drug Market Size and Volume Forecast by Country
10.2.1. Brazil
10.2.2. Mexico
10.2.3. Rest of Latin America
10.3. Absolute $ Opportunity Assessment by Country
10.4. Latin America Anti-tumor Drug Market Size and Volume Forecast by Application
10.4.1. Alkylating Agents
10.4.2. Anti-metabolism Drugs
10.4.3. Platinum Antineoplastic Agents
10.4.4. Anthracycline antitumor drugs
10.4.5. Microtubule Stabilizer
10.4.6. Endocrine Therapy Drugs
10.4.7. Immunotherapy Drugs
10.4.8. Gene Therapy Drugs
10.4.9. Targeted Antineoplastic Drugs
10.5. Basis Point Share (BPS) Analysis by Application
10.6. Y-o-Y Growth Projections by Application
10.7. Latin America Anti-tumor Drug Market Size and Volume Forecast by Type
10.7.1. Cytotoxic Drugs
10.7.2. Non-cytotoxic Drugs
10.7.3. Anti-tumor Dru
10.8. Basis Point Share (BPS) Analysis by Type
10.9. Y-o-Y Growth Projections by Type
10.10. Market Attractiveness/Growth Potential Analysis
10.10.1. By Country
10.10.2. By Product Type
10.10.3. By Application
10.10.4. By Sales Channel
10.11. Latin America Anti-tumor Drug Demand Share Forecast, 2019-2026
11. Europe Anti-tumor Drug Market Analysis and Forecast
11.1. Introduction
11.1.1. Basis Point Share (BPS) Analysis by Country
11.1.2. Y-o-Y Growth Projections by Country
11.1.3. Europe Average Pricing Analysis
11.2. Europe Anti-tumor Drug Market Size and Volume Forecast by Country
11.2.1. Germany
11.2.2. France
11.2.3. Italy
11.2.4. U.K.
11.2.5. Spain
11.2.6. Russia
11.2.7. Rest of Europe
11.3. Absolute $ Opportunity Assessment by Country
11.4. Europe Anti-tumor Drug Market Size and Volume Forecast by Application
11.4.1. Alkylating Agents
11.4.2. Anti-metabolism Drugs
11.4.3. Platinum Antineoplastic Agents
11.4.4. Anthracycline antitumor drugs
11.4.5. Microtubule Stabilizer
11.4.6. Endocrine Therapy Drugs
11.4.7. Immunotherapy Drugs
11.4.8. Gene Therapy Drugs
11.4.9. Targeted Antineoplastic Drugs
11.5. Basis Point Share (BPS) Analysis by Application
11.6. Y-o-Y Growth Projections by Appliation
11.7. Europe Anti-tumor Drug Market Size and Volume Forecast by Type
11.7.1. Cytotoxic Drugs
11.7.2. Non-cytotoxic Drugs
11.7.3. Anti-tumor Dru
11.8. Basis Point Share (BPS) Analysis by Type
11.9. Y-o-Y Growth Projections by Type
11.10. Market Attractiveness/Growth Potential Analysis
11.10.1. By Country
11.10.2. By Product Type
11.10.3. By Application
11.10.4. By Sales Channel
11.11. Europe Anti-tumor Drug Demand Share, 2019-2026
12. Asia Pacific Anti-tumor Drug Market Analysis and Forecast
12.1. Introduction
12.1.1. Basis Point Share (BPS) Analysis by Country
12.1.2. Y-o-Y Growth Projections by Country
12.1.3. Asia Pacific Average Pricing Analysis
12.2. Asia Pacific Anti-tumor Drug Market Size and Volume Forecast by Country
12.2.1. China
12.2.2. Japan
12.2.3. South Korea
12.2.4. India
12.2.5. Australia
12.2.6. Rest of Asia Pacific (APAC)
12.3. Absolute $ Opportunity Assessment by Country
12.4. Asia Pacific Anti-tumor Drug Market Size and Volume Forecast by Application
12.4.1. Alkylating Agents
12.4.2. Anti-metabolism Drugs
12.4.3. Platinum Antineoplastic Agents
12.4.4. Anthracycline antitumor drugs
12.4.5. Microtubule Stabilizer
12.4.6. Endocrine Therapy Drugs
12.4.7. Immunotherapy Drugs
12.4.8. Gene Therapy Drugs
12.4.9. Targeted Antineoplastic Drugs
12.5. Basis Point Share (BPS) Analysis by Application
12.6. Y-o-Y Growth Projections by Application
12.7. Asia Pacific Anti-tumor Drug Market Size and Volume Forecast by Type
12.7.1. Cytotoxic Drugs
12.7.2. Non-cytotoxic Drugs
12.7.3. Anti-tumor Dru
12.8. Basis Point Share (BPS) Analysis by Type
12.9. Y-o-Y Growth Projections by Type
12.10. Market Attractiveness/Growth Potential Analysis
12.10.1. By Country
12.10.2. By Product Type
12.10.3. By Application
12.10.4. By Sales Channel
12.11. Asia Pacific Anti-tumor Drug Demand Share, 2019-2026
13. Middle East & Africa Anti-tumor Drug Market Analysis and Forecast
13.1. Introduction
13.1.1. Basis Point Share (BPS) Analysis by Country
13.1.2. Y-o-Y Growth Projections by Country
13.1.3. Asia Pacific Average Pricing Analysis
13.2. Middle East & Africa Anti-tumor Drug Market Size and Volume Forecast by Country
13.2.1. Saudi Arabia
13.2.2. South Africa
13.2.3. UAE
13.2.4. Rest of Middle East & Africa (MEA)
13.3. Absolute $ Opportunity Assessment by Country
13.4. Middle East & Africa Anti-tumor Drug Market Size and Volume Forecast by Application
13.4.1. Alkylating Agents
13.4.2. Anti-metabolism Drugs
13.4.3. Platinum Antineoplastic Agents
13.4.4. Anthracycline antitumor drugs
13.4.5. Microtubule Stabilizer
13.4.6. Endocrine Therapy Drugs
13.4.7. Immunotherapy Drugs
13.4.8. Gene Therapy Drugs
13.4.9. Targeted Antineoplastic Drugs
13.5. Basis Point Share (BPS) Analysis by Application
13.6. Y-o-Y Growth Projections by Application
13.7. Middle East & Africa Anti-tumor Drug Market Size and Volume Forecast by Type
13.7.1. Cytotoxic Drugs
13.7.2. Non-cytotoxic Drugs
13.7.3. Anti-tumor Dru
13.8. Basis Point Share (BPS) Analysis by Type
13.9. Y-o-Y Growth Projections by Type
13.10. Market Attractiveness/Growth Potential Analysis
13.10.1. By Country
13.10.2. By Product Type
13.10.3. By Application
13.10.4. By Sales Channel
13.11. Middle East & Africa Anti-tumor Drug Demand Share, 2019-2026
14. Competition Landscape
14.1. Global Anti-tumor Drug Market: Market Share Analysis
14.2. Anti-tumor Drug Distributors and Customers
14.3. Anti-tumor Drug Market: Competitive Dashboard
14.4. Company Profiles (Details Overview, Financials, Developments, Strategy)
14.4.1. Roche
14.4.1.1. Overview
14.4.1.2. Financials
14.4.1.3. Developments
14.4.1.4. Strategic Outlook
14.4.2. Novartis
14.4.2.1. Overview
14.4.2.2. Financials
14.4.2.3. Developments
14.4.2.4. Strategic Outlook
14.4.3. Celgene
14.4.3.1. Overview
14.4.3.2. Financials
14.4.3.3. Developments
14.4.3.4. Strategic Outlook
14.4.4. Bristol-Myers Squibb
14.4.4.1. Overview
14.4.4.2. Financials
14.4.4.3. Developments
14.4.4.4. Strategic Outlook
14.4.5. Amgen
14.4.5.1. Overview
14.4.5.2. Financials
14.4.5.3. Developments
14.4.5.4. Strategic Outlook
14.4.6. Johnson & Johnson
14.4.6.1. Overview
14.4.6.2. Financials
14.4.6.3. Developments
14.4.6.4. Strategic Outlook
14.4.7. Pfizer
14.4.7.1. Overview
14.4.7.2. Financials
14.4.7.3. Developments
14.4.7.4. Strategic Outlook
14.4.8. Takeda
14.4.8.1. Overview
14.4.8.2. Financials
14.4.8.3. Developments
14.4.8.4. Strategic Outlook
14.4.9. Eli Lilly
14.4.9.1. Overview
14.4.9.2. Financials
14.4.9.3. Developments
14.4.9.4. Strategic Outlook
14.4.10. AstraZeneca
14.4.10.1. Overview
14.4.10.2. Financials
14.4.10.3. Developments
14.4.10.4. Strategic Outlook
14.4.11. Astellas
14.4.11.1. Overview
14.4.11.2. Financials
14.4.11.3. Developments
14.4.11.4. Strategic Outlook
14.4.12. Merck & Co
14.4.12.1. Overview
14.4.12.2. Financials
14.4.12.3. Developments
14.4.12.4. Strategic Outlook
14.4.13. Sanofi
14.4.13.1. Overview
14.4.13.2. Financials
14.4.13.3. Developments
14.4.13.4. Strategic Outlook
14.4.14. Bayer
14.4.14.1. Overview
14.4.14.2. Financials
14.4.14.3. Developments
14.4.14.4. Strategic Outlook
14.4.15. Biogen Idec
14.4.15.1. Overview
14.4.15.2. Financials
14.4.15.3. Developments
14.4.15.4. Strategic Outlook
14.4.16. Eisai
14.4.16.1. Overview
14.4.16.2. Financials
14.4.16.3. Developments
14.4.16.4. Strategic Outlook
14.4.17. Teva
14.4.17.1. Overview
14.4.17.2. Financials
14.4.17.3. Developments
14.4.17.4. Strategic Outlook
14.4.18. Otsuka
14.4.18.1. Overview
14.4.18.2. Financials
14.4.18.3. Developments
14.4.18.4. Strategic Outlook
14.4.19. Anti-tumor Dru
14.4.19.1. Overview
14.4.19.2. Financials
14.4.19.3. Developments
14.4.19.4. Strategic Outlook
14.4.20. COMPANY 20
14.4.20.1. Overview
14.4.20.2. Financials
14.4.20.3. Developments
14.4.20.4. Strategic Outlook
